Idioma:

Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck

Thomson, David J. ; Silva, Priyamal ; Denton, Kim ; Bonington, Suzanne ; Mak, Soo K. ; Swindell, Ric ; Homer, Jarrod ; Sykes, Andrew J. ; Lee, Lip W. ; Yap, Beng K. ; Slevin, Nicholas J.

Head & neck, 2015-02, Vol.37 (2), p.182-187 [Periódico revisado por pares]

United States: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck
Autor: Thomson, David J. ; Silva, Priyamal ; Denton, Kim ; Bonington, Suzanne ; Mak, Soo K. ; Swindell, Ric ; Homer, Jarrod ; Sykes, Andrew J. ; Lee, Lip W. ; Yap, Beng K. ; Slevin, Nicholas J.
Assuntos: adenoid cystic carcinoma ; Adult ; Aged ; Carcinoma, Adenoid Cystic - drug therapy ; Carcinoma, Adenoid Cystic - mortality ; Disease Progression ; Female ; Humans ; Male ; Middle Aged ; Niacinamide - analogs & derivatives ; Niacinamide - therapeutic use ; Phenylurea Compounds - therapeutic use ; Protein Kinase Inhibitors - therapeutic use ; Salivary Gland Neoplasms - drug therapy ; Salivary Gland Neoplasms - mortality ; sorafenib ; trial
É parte de: Head & neck, 2015-02, Vol.37 (2), p.182-187
Notas: istex:5539A1275766B6A81A2F01B65AA8EF854EC8F405
ArticleID:HED23577
ark:/67375/WNG-SKLHX262-4
The Christie NHS Foundation Trust. The study drug was received from Bayer Schering Pharmaceuticals.
This work was presented in part at the European Society for Radiotherapy and Oncology, Barcelona, Spain, May 9–13, 2012.
Descrição: Background There is a need to improve the systemic treatment of advanced adenoid cystic carcinoma (ACC). Response rates to chemotherapy are poor and preliminary investigations of molecularly targeted agents have been disappointing. In this study, we evaluate sorafenib, an oral multikinase inhibitor, which has an attractive targeting profile for this disease. Methods In a single‐arm phase II trial, patients with unresectable locally recurrent and/or metastatic ACC were treated with sorafenib 400 mg bid. Results Twenty‐three patients, median age 51 years, were recruited from 2009 to 2011. Median progression‐free survival (PFS) and overall survival (OS) were 11.3 and 19.6 months, respectively. PFS at 6 and 12 months were 69.3% and 46.2%, respectively. Sorafenib was only reasonably well tolerated, and 13 patients (57%) experienced grade 3 toxicity. Conclusion Sorafenib showed modest activity in ACC with a 12‐month PFS of 46.2%. Sorafenib 400 mg bid was associated with significant toxicity and, taken together with limited effectiveness, cannot be enthusiastically recommended for further evaluation. © 2014 Wiley Periodicals, Inc. Head Neck 37: 182‐187, 2015
Editor: United States: Blackwell Publishing Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 4 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck

Thomson, David J. ; Silva, Priyamal ; Denton, Kim ; Bonington, Suzanne ; Mak, Soo K. ; Swindell, Ric ; Homer, Jarrod ; Sykes, Andrew J. ; Lee, Lip W. ; Yap, Beng K. ; Slevin, Nicholas J.

United States: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.